💊 Short-Acting Beta-2 Agonists (SABA)

Short-acting beta-2 agonists (SABAs) are a class of bronchodilator medications used for rapid relief of bronchoconstriction. They are often referred to as 'reliever' inhalers.

SABAs selectively stimulate beta-2 adrenergic receptors located on the smooth muscle cells of the airways. Activation of these receptors leads to increased intracellular cyclic AMP (cAMP) levels. This rise in cAMP causes relaxation of bronchial smooth muscle, resulting in bronchodilation and improved airflow.

SABAs are indicated for the rapid relief of asthma symptoms, such as wheezing, breathlessness, and chest tightness. They are also used for the prevention of exercise-induced bronchoconstriction. In chronic obstructive pulmonary disease (COPD), they provide symptomatic relief of breathlessness and are used on an as-needed basis.

There are no absolute contraindications to SABAs in acute severe asthma where the benefits outweigh the risks. However, caution is advised in patients with severe cardiovascular disease, arrhythmias, or uncontrolled hyperthyroidism due to potential systemic effects. Hypersensitivity to the drug is also a contraindication.

Common side effects include fine tremor, particularly of the hands, and palpitations or tachycardia. Headache and muscle cramps can also occur. Paradoxical bronchospasm is a rare but serious adverse effect. Excessive use can lead to hypokalaemia and cardiac arrhythmias.

Patients should be monitored for the frequency of SABA use, as increasing reliance can indicate poorly controlled asthma. In acute settings, heart rate, blood pressure, and oxygen saturation should be monitored. Serum potassium levels may be checked in cases of very high or prolonged dosing.

When prescribing, confirm the patient's allergy status, especially to other inhalers. Counsel patients on the correct inhaler technique and the importance of using it only when needed for symptom relief. Advise them to seek medical review if they are using their SABA more than a few times a week, as this suggests inadequate asthma control.

SABAs (e.g., salbutamol, terbutaline) provide rapid bronchodilation for acute asthma symptoms and exercise-induced bronchoconstriction. They are 'reliever' medications. Overuse indicates poor asthma control and can lead to side effects like tremor, palpitations, and hypokalaemia. They should not be used as monotherapy for persistent asthma.

SBAs often test the appropriate use of SABAs as 'relievers' and the implications of their overuse (e.g., poor asthma control, hypokalaemia). Questions may also focus on their rapid onset of action and their role in exercise-induced asthma. Distinguishing SABAs from LABAs in terms of duration of action is a common theme.